Advertisement

BMC Cancer

, 19:1124 | Cite as

The oncogene Gankyrin is expressed in testicular cancer and contributes to cisplatin sensitivity in embryonal carcinoma cells

  • Maria E. Camacho-Moll
  • Joni Macdonald
  • L. H. J. Looijenga
  • Michael P. Rimmer
  • Roland Donat
  • John A. Marwick
  • C. J. Shukla
  • Neil Carragher
  • Anne Jørgensen
  • Rod T. MitchellEmail author
Open Access
Research article
Part of the following topical collections:
  1. Cell and molecular biology

Abstract

Background

Testicular germ cell cancer (TGCC) develops from pre-malignant germ neoplasia in situ (GCNIS) cells. GCNIS originates from fetal gonocytes (POU5F1+/MAGE-A4), which fail to differentiate to pre-spermatogonia (POU5F1/MAGE-A4+) and undergo malignant transformation. Gankyrin is an oncogene which has been shown to prevent POU5F1 degradation and specifically interact with MAGE-A4 in hepatocellular carcinoma (HCC) cells. We aimed to investigate the role of Gankyrin in progression from gonocyte to pre-invasive GCNIS and subsequent invasive TGCC.

Methods

We determined Gankyrin expression in human fetal testicular tissue (gestational weeks 9–20; n = 38), human adult testicular tissue with active spermatogenesis (n = 9), human testicular tissue with germ cell maturation delay (n = 4), testicular tissue from patients with pre-invasive GCNIS (n = 6), and invasive TGCC including seminoma (n = 6) and teratoma (n = 7). Functional analysis was performed in-vitro by siRNA knock-down of Gankyrin in the NTera2 cells (derived from embryonal carcinoma).

Results

Germ cell expression of Gankyrin was restricted to a sub-population of prespermatogonia in human fetal testes. Nuclear Gankyrin was also expressed in GCNIS cells of childhood and adult pre-invasive TGCC patients, and in GCNIS from seminoma and non-seminoma patients. Cytoplasmic expression was observed in seminoma tumour cells and NTera2 cells. Gankyrin knock-down in NTera2 cells resulted in an increase in apoptosis mediated via the TP53 pathway, whilst POU5F1 expression was unaffected. Furthermore, Gankyrin knock-down in NTera2 cells increased cisplatin sensitivity with an increase in cell death (13%, p < 0.05) following Gankyrin knock-down, when compared to cisplatin treatment alone, likely via BAX and FAS. Our results demonstrate that Gankyrin expression changes in germ cells during normal transition from gonocyte to prespermatogonia. In addition, changes in Gankyrin localisation are associated with progression of pre-invasive GCNIS to invasive TGCC. Furthermore, we found that Gankyrin is involved in the regulation of NTera2 cell survival and that a reduction in Gankyrin expression can modulate cisplatin sensitivity.

Conclusions

These results suggest that manipulation of Gankyrin expression may reduce the cisplatin dose required for the treatment of TGCC, with benefits in reducing dose-dependent side effects of chemotherapy. Further studies are required in order to assess the effects of modulating Gankyrin on GCNIS/TGCC using in vivo models.

Keywords

Gankyrin Testicular germ cell cancer GCNIS Apoptosis Cisplatin sensitivity 

Abbreviations

DSD

Disorders of Sex Development

GCNIS

Germ Cell Neoplasia in situ

HCC

Hepatocelular Carcinoma

NChS

Normal Chicken Serum

RIPA

Radioimunoprecipitation Assay

TBS

Tris Buffer Saline

TGCC

Testicular Germ Cell Cancer

Background

The incidence of testicular germ cell cancer (TGCC) has increased over recent decades and is currently the most common malignancy among young caucasian men [1, 2, 3]. The precursor lesion for TGCC, known as Germ Cell Neoplasia in situ (GCNIS, previously carcinoma in situ) originates during fetal life when a sub-population of gonocytes fail to differentiate normally to (pre) spermatogonia [4, 5]. Several studies have shown that GCNIS cells resemble gonocytes with regard to morphology, epigenetic profile and protein expression [6, 7, 8]. GCNIS cells remain dormant in the testis until after puberty, when they gain invasive capacity and develop into invasive tumours [9, 10], histologically classified as seminoma and non-seminoma [11]. Although models for the pathogenesis of TGCC have been hypothesized [12], the mechanisms that result in failure of gonocyte differentiation, development of GCNIS, and stimulation of proliferation of GCNIS to gain invasive capacity to form TGCC are incompletely understood, although an interaction within (epi) genetics and environmental parameters are assumed [13].

All gonocytes and GCNIS cells express the pluripotency factor POU5F1 (OCT4), whilst a sub-population of GCNIS cells also express the (pre) spermatogonial protein MAGE-A4. We have previously shown that MAGE-A4 GCNIS cells proliferate more frequently than the MAGE-A4+ population, suggesting that MAGE-A4 might have an anti-proliferative effect when expressed in GCNIS cells [14].

Gankyrin is an oncogene that has previously been shown to be involved in the pathogenesis of several cancers including colorectal cancer [15, 16], breast cancer [17, 18, 19] and hepatocelullar carcinoma [20, 21, 22, 23, 24, 25]. MAGE-A4 has been shown to suppress the oncogenic properties of Gankyrin leading to reduced tumour size in a mouse model of Gankyrin overexpression [26]. Gankyrin also prevents POU5F1 degradation in hepatocellular carcinoma (HCC) by inhibiting the interaction of POU5F1 with WW domain containing E3 ubiquitin protein ligase (WWP2 [23, 27];. POU5F1 has also been shown to be negatively regulated by WWP2 in NTera2 (embryonal carcinoma) cells [27].

Cisplatin based chemotherapy is frequently used for treatment of TGCC, resulting in a high cure rate [28, 29]. However, cisplatin treatment also results in significant adverse effects in patients which includes infertility. It has been hypothesized that the efficiency of cisplatin based chemotherapy in TGCC is due at least in part to the high expression of wildtype TP53 in TGCC [30, 31]. It has been previously shown that TP53 is required by cisplatin to facilitate cytotoxicity [32] and that the predominant mechanism of cisplatin cytotoxicity in TGCC is due toTP53 hypersensitivity [33]. This has been demonstrated in the TGCC cell line NTera2 and 2102EP [34]. Gankyrin has been linked to TP53 in HCC [22, 35], where it has been shown that Gankyrin mediates the degradation of tumour suppressor proteins such as TP53 [36, 37]. However, there have been no previous studies examining the effect of Gankyrin manipulation on TP53 and downstream signalling in TGCC.

We hypothesized that Gankyrin expression in the human fetal testis is associated with germ cell maturation and malignant transformation. We also hypothesized that Gankyrin regulates the oncogenic potential and cisplatin sensitivity of NTera2 cells via the TP53 pathway.

Methods

The study aim was to characterize Gankyrin expression in human testicular tissues from fetal life through adulthood and to compare with GCNIS and TGCC. Furthermore, we aimed to investigate the impact of Gankyrin knockdown on cell death and cisplatin sensitivity in embryonal carcinoma cells.

Tissue collection

Human fetal testis tissue

Human fetal testicular tissue was obtained following elective termination of pregnancy during gestational weeks 9 to 20 (n = 38). Women gave informed consent and tissue was collected with ethical approval (REC reference: LREC08/1101/1 and 08/H0906/21 + 5). Gestational age was determined by ultrasound and confirmed by measuring foot length. Testis tissue was fixed in formalin for 24 h, transferred into 70% ethanol and then embedded in paraffin. Sections of 5 μm thickness were prepared. Sex was determined by expression of sex determining region gene Y (SRY) gene by qPCR as previously described [38].

Adult testicular tissue

Testicular tissue with complete spermatogenesis (n = 9) was obtained from archived material. Orchiectomy was performed for clinical indications primarily involving chronic testicular pain. Tissues were fixed in buffered formalin for pathological assessment. Ethical approval was obtained for the use of archived human testicular tissue from the pathology department at the Western General Hospital in Edinburgh (REC Reference: 10/S1402/33) and from the biobank at the Department of Growth and Reproduction, University Hospital of Copenhagen, Denmark (H-1-2012-007).

Childhood testicular samples with maturation delay

Tissue from children aged 0–2 years with maturation delay (n = 4) were obtained from Erasmus MC-University Medical Center, Rotterdam (Institutional review board – MEC 02.981 and CCR2041). Tissues were obtained in the context of routine clinical diagnosis of suspected gonadal anomalies to be evaluated by histological examination. The samples were handled according to existing standard operational protocols and evaluated by an experienced clinical uro-pathologist. Left over tissue was approved to be used for scientific research. The diagnosis of maturation delay is reached when in children above 6 months, POU5F1+ germ cells with round nuclei present in the lumen of a seminiferous tubule can be observed [39].

TGCC samples

Tissue from children (n = 2) and adults (n = 4) with pre-invasive disease (pre-GCNIS cells or GCNIS cells without evidence of invasive tumour) were obtained from Erasmus MC-University Medical Center, Rotterdam (Institutional review board – MEC 02.981 and CCR2041) and from the biobank at the Department of Growth and Reproduction, University Hospital of Copenhagen, Copenhagen, Denmark (H-1-2012-007). Samples from pre-GCNIS patients were diagnosed by the presence of OCT4+ cells which can co-express TSPY in a heterogeneous pattern accompanied by focal KITLG expression. These cells been relocated from the center of the tubule to the pre-spermatogonial niche at the basement membrane [39]. These tissues were obtained from patients with Disorders of Sexual Development (DSD), infertility, or suspected TGCC for diagnostic purposes. Invasive TGCC tissue was obtained from clinical orchiectomy specimens from men with seminoma, (n = 6) and teratoma (n = 7). These tissues contained regions with histologically normal spermatogenesis, GCNIS cells or the tumour component. Tissues were randomly selected and the presence of GCNIS cells was confirmed by light microscopy prior to commencing the study.

Triple immunofluorescence

Sections were dewaxed in xylene, rehydrated in graded alcohols and washed in tap water. Antigen retrieval was performed in 0.01 M citrate buffer in a decloaking chamber (Biocare Medical, Berkshire, UK), sections were then washed in tap water and endogenous peroxidase was blocked with 3% H2O2 in MeOH for 30 min, followed by two washes in Tris Buffer saline (TBS) for 5 min. Sections were blocked with Normal chicken serum (NChS) for 30 min at room temperature (RT) followed by incubation with POU5F1 antibody (Santa Cruz, Heidelberg, Germany – sc8628) overnight at 4 °C. The following day sections were washed twice with TBS for 5 min each and incubated with chicken anti goat peroxidase labelled antibody (1 in 200 in NChS) for 30 min, followed by two 5 min washes with TBS and incubation with Tyramide signal amplification (TSA, Perkin Elmer, Waltham, USA), at 1:50 for 10 min. Sections were microwaved for 2.5 min in 0.01 M citrate buffer, followed by a 30 min cool down period. The process from NChS block up to primary antibody detection was repeated twice more for two subsequent primary antibodies MAGE-A4 (gift, described in [40, 41]) and Gankyrin (Novus Bio – NBP1–82443). Sections were counterstained with DAPI (4′, 6-diamidino-2-phenylindole, Sigma, Poole, UK) by adding 1 μl/mL of TBS and incubating the sections for 10 min in the dark. Finally, sections were washed twice with TBS for 5 min and mounted with PermaFluor (Life Technologies, Paisley, UK). Negative controls were no primary antibody controls and are shown as insets. Details of antibodies used for immunofluorescence can be found in Table 1.
Table 1

Details of primary antibodies

Antibody

Laboratory

Immunofluorescence

Western blot

Gankyrin

Novus

1 in 10,000

1 in 1000

GAPDH

Abcam

N/A

1:5000

MAGE-A4

gift

1:300

N/A

POU5F1

Santa Cruz

1:150

1:300

SOX9

Merck Millipore

1:5000

N/A

TP53

Santa Cruz

1:1000

1:1000

Tubulin

Abcam

N/A

1:5000

Western blot

NTera2 cells were resuspended in 50 μl of radioimmunoprecipitation assay (RIPA) buffer with protease inhibitors (Roche, Baser, Switzerland). Bradford assay was used to quantify the amount of protein in each sample and Western blot was performed with 20 μg of protein in each lane. Protein was loaded into wells of a NOVEX SDS/PAGE (Life Technologies) gel, which was run at 150 mA with running buffer (Thermofisher scientific). Protein was transferred to an Amersham Hybond ECL nitrocellulose membrane (GE Healthcare Lifesciences, Buckinghamshire, UK) at 400 V, 250 mA and 50 W for 90 min. Membranes were then blocked with 5% skimmed milk powder in PBST (PBS + Tween®20) for 30 min at RT, followed by incubation overnight with the relevant primary antibody diluted in 5% skimmed milk in PBST at 4 °C. The following day membranes were incubated for 30 min at RT with a secondary antibody conjugated with IRDye 680 or 800 (LI-COR Biosciences, Nebraska, USA) at a concentration of 1 in 10,000, and scanned in the LI-COR Odyssey scanner (LI-COR Biosciences). Images were captured by Image Studio™ (Li-COR Biosciences) software. Tubulin or Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) detection were used as loading controls. Relative protein expression was quantified with Image Studio™.. Primary antibody details can be found on Table 1.

Quantification of nuclear Gankyrin expression

POU5F1 was used to detect GCNIS cells in triple immunostained sections from pre-invasive and invasive TGCC patients. For each section,10 random fields with GCNIS were quantified using a LSM710 Zeiss confocal microscope (Carl Zeiss). For sections containing smaller areas of GCNIS, all GCNIS cells were counted. These images were then compiled using Image J software (Image J, U. S. National Institutes of Health, Bethesda, Maryland, USA). POU5F1+/MAGE-A4 and POU5F1+/MAGE-A4 GCNIS cells were counted using the cell counter plug-in in the Image J software. Data was analysed with GraphPad Prism 6.04 (GraphPad software INC., La Jolla, USA).

Gankyrin SiRNA transfection of NTera2 cells

NTera2 cells were cultured with DMEM +1x glutamine +1x penicillin/streptomycin +10x FCS (all reagents from ThermoFisher Scientific) at 37 °C and 5%CO2. Cells were seeded in 12 well plates with 10 × 104 cells per well on the day prior to transfection. Cells were transfected with 20 nM of Gankyrin siRNA using HiPerFect (Qiagen, Redwood City, C. A, U.S.A) transfection reagent diluted in DMEM + glutamine. Gankyrin siRNA (Life Technologies, Paisley, UK) with the sequence 5′-UUU CGA AGC UGC AUA AUG UAA GGG A-3′ was used for transfection of NTera2 cells. Controls included a media only and siRNA control. After randomization of the plate, cells were incubated at 37 °C and 5% CO2 for 10 h with Gankyrin siRNA or siRNA control. After 10 h the media was discarded and replaced by pre-warmed complete medium (DMEM + 5%FCS + 1x penicillin/streptomycin +1x glutamine). Cells were then harvested 24 or 48 h after transfection had commenced. RNA or protein was extracted and stored at − 80 °C until further analysis. Cells were counted using the NucleoCounter NC-100 automated cell count system (Chemometec, Allerod, Denmark). For in vitro experiments, a minimum of three replicates per experiment were included. These three replicates were considered as the experimental unit (n). Experiments were repeated a minimum of three times (n = 3).

Modulation of Cisplatin effects in NTera2 cells

Cisplatin kill curve in NTera2 cells

In order to determine the optimal cisplatin concentration for moderate (~ 50%) cell death, 12 well plates were seeded with 10 × 104 NTera2 cells. The following day (D1), plates were randomized for treatment with 0.25, 0.5, 1, 2, 4, 8, 16 or 100 μM cisplatin for 24 h. On D2, media was discarded, cells were washed with 1 ml DPBS (GIBCO, Hemel Hempstead, UK), and cells were dissociated with 250 μl TrypLE™ Express (Life technologies) for 5 min at 37 °C. Pre-warmed complete medium (750 μl) was added and the suspension was collected. Cells were centrifuged for 5 min at 4000 rpm. Media was discarded, and cells resuspended in 1 ml media. From this suspension 100 μL was taken for cells counts in the NucleoCounter NC-100 Automated cell count system (Chemometec). The dose to be used in further experiments was 4 μM of cisplatin for 24 h which corresponded to ~ 50% cell death.

Gankyrin siRNA in cisplatin treated NTera2 cells

To investigate the effects of Gankyrin knock-down on cisplatin sensitivity on NTera2 cells, cisplatin treatments (24 h) was initiated following transfection with siRNA targeting Gankyrin expression for 24 h. Cells were then harvested and quantified in the NucleoCounter NC-100 automated cell count system (Chemometec).

Cell cycle analysis

Cell cycle analysis was performed in a 5 laser LSR Fortessa (BD Bioscience) flow cytometer. DNA was stained with HOECHST (Cell Signalling) and viability assessment was performed with propidium iodide staining. After harvesting cells as described above for the modulation of cisplatin effects in NTera2 cells section, cells were resuspended in a 15 μg/μl HOECHST (diluted in 2%FCS DPBS) solution and incubated in the dark for 30 min at 37 °C prior to cell cycle analysis.

Apoptosis assay

NTera2 cells were cultured with DMEM +1x glutamine + 10% FCS (ThermoFisher Scientific) at 37 °C and 5% CO2 using the IncuCyte Live Cell Analysis System (Sartorious, Goettingen, Germany). Cells were seeded in 96 well plates (Corning), 15 × 104 cells per well 24 h prior transfection to reach 80–90% confluence. NTera2 cells were cultured with media only, Gankyrin siRNA (100 μM; Qiagen) or siRNA control. Staurosporine (300 nM; Sigma, Missouri, US) was used as a positive control for apoptosis. Following 10 h incubation, media was replaced with the fluorogenic caspase biosensor, NucView 488 (Biotium, Fremont, C. A, U.S.A) diluted in DMEM +1x glutamine + 10% FCS, to detect Cleaved Caspase-3 substrate in cells. Cells were visualised and images were obtained at 72 h, using an IncuCyte™ live cell imaging instrument and 20X Objective (Sartorius AG).

qPCR

RNA was extracted as per manufacturer’s instructions using the Qiagen minikit (Qiagen, Hilden Germany), and RNA quality/quantity was assessed using a NanoDrop (Thermofisher Scientific, Massachusetts, US). cDNA synthesis was performed according to manufacturer’s instructions using the MAXIMA first strand cDNA synthesis kit (ThermoFisher Scientific). qPCR was performed with SYBR green (Agilent technologies, Santa Clara, California, USA), according to manufacturer’s instructions. RPS20 was used as housekeeping gene [42] and expression levels of Gankyrin, POU5F1, RB1, CDK4; TP53 and its downstream genes P21, BAX, FAS, PAI, BAI and proliferation genes Ki67, PCNA and TPX2 was investigated. Primer details are described in Table 2.
Table 2

Primers sequences used for qPCR

Gene

Forward Primer

Reverse Primer

BAI1

CTAAGATGGCGAAGGTGGAG

CTGTGGGATGAGACGGATGT

BAX

GAGGATGATTGCCGCCGTGGACA

GGTGGGGGAGGAGGCTTGAGG

FAS

TGCACCCGGACCCAGAATAC

GAAGACAAAGCCACCCCAAGTTAG

Gankyrin

ATGAGGCTACAGCAATGCAC

TACTTGCTCCTTGGGACACC

KI67

GAGGTGTGCAGAAAATCCAAA

CTGTCCCTATGACTTCTGGTTGT

P21

CTGGCTCTTGATACCCCCCT

TCAACACTGAGACGGGCTCC

PAI1

TGCTGGTGAATGCCCTCTACT

CGGTCATTCCCAGGTTCTCTA

PCNA

ACACGATTGGCCCTAAAGTCTTCCC

GACCACTCTGCTACGCCTGCAACCG

POU5F1

CTTCTGCTTCAGGAGCTTGG

GAAGGAGAAGCTGGAGCAAA

RPS20

AACAAGCCGCAACGTAAAATC

ACGATCCCACGTCTTAGAACC

SRY

ACAGTAAAGGCAACGTCCAG

ATCTGCGGGAAGCAAACTGC

TP53

TCCACTACAACTACATGTGTAAC

GTGAAATATTCTCCATCCAGTG

Statistical analysis

Statistical analysis for all experiments was performed by paired t-test using Graphpad prism 6.04 (GraphPad software INC., La Jolla, USA). For each experiment a minimum of n = 3 (each with at least 3 technical replicates) were used.

Results

Gankyrin is not expressed in gonocytes, but in a subset of pre-spermatogonia in normal human fetal and adult testis

In human fetal testis, triple immunofluorescent staining with POU5F1, MAGE-A4 and Gankyrin was performed. Nuclear expression of Gankyrin could not be detected in gonocytes (POU5F1+/MAGE-A4, yellow arrows, Fig. a and b), but in a subset of pre-spermatogonia (POU5F1/MAGE-A4+, white arrows, Fig. 1b), nuclear Gankyrin expression was found. Gankyrin was also expressed in a subset of spermatogonia in adult testis tissue with full spermatogenesis (blue arrows, Fig. 1c). Abundant Sertoli cell expression of Gankyrin was present in both normal fetal and adult testis (orange arrows, Fig. 1).
Fig. 1

Representative images for Gankyrin expression in human fetal testis and normal adult testis. Gankyrin (red), POU5F1 (green; gonocyte) and MAGE-A4 (blue; prespermatogonia) expression in A), 11 week and B) 18 week old human fetal testis, counterstained with DAPI, yellow arrows – gonocytes, white arrows – pre-spermatogonia, green arrows – differentiating gonocyte, orange arrows – Sertoli cells, Scalebars – 50 μm. C) Representative image of Gankyrin expression in normal human adult testis immunostained for SOX9 (cyan; Sertoli cells), POU5F1 (green), MAGE-A4 (blue; spermatogonia) and Gankyrin (red), Cyan arrow – spermatogonia. Scalebars – 50 μm, insets – no primary antibody controls. w-weeks.

Nuclear Gankyrin is expressed in a subset of GCNIS in tissue from patients with pre-invasive or invasive TGCC

According to TGCC pathogenesis, there is a block of differentiation of gonocytes, which then become GCNIS and remain in the testis. After puberty these cells give rise to tumours. The gonocytes are the precursor cells of GCNIS and therefore the expression profile of gonocytes compared to GCNIS is important to examine potential mechanism of malignant transformation. In human fetal testis, gonocytes did not express nuclear Gankyrin whereas in samples with maturation delay and in GCNIS from both pre-pubertal and adult patients with pre-invasive TGCC, nuclear Gankyrin was observed (yellow arrows, Fig. 2). Similarly, nuclear Gankyrin expression was observed in a subset of GCNIS cells from adult patients with invasive TGCC (yellow arrows, Fig. 3a-d). In order to examine whether there was a difference in nuclear Gankyrin expression between MAGE-A4+ and MAGE-A4 GCNIS cells in GCNIS from patients with pre-invasive (n = 6) and invasive (n = 6) TGCC, we quantified Gankyrin expression in each sub-population. An increased proportion of nuclear Gankyrin expression was observed in POU5F1+/MAGE-A4 GCNIS compared to POU5F1+/MAGE-A4+ GCNIS (Fig. S1). Gankyrin was also detected in the cytoplasm of seminoma tumour cells and the seminoma component of mixed non-seminoma, which was determined by POU5F1 expression (Fig. 3e and f).
Fig. 2

Gankyrin expression pre-invasive germ cells. a) 1 year old - maturation delay; b) 2 year old – maturation delay; c) 7 year old pre-invasive TGCC; d)17 year old pre-invasive TGCC; and e) 23 year old pre-invasive TGCC. Yellow arrows – GCNIS cells, orange arrows – Sertoli cells. This experiment was performed along with human fetal testis samples, no primary antibody control is the same as on Fig. 1, Scalebars - 50 μm.

Fig. 3

Gankyrin expression in invasive TGCC. a-d Gankyrin (red), POU5F1 (green; GCNIS cells), and MAGE-A4 (blue; spermatogonia) expression in GCNIS containing tubules from patients with invasive TGCC, yellow arrows – GCNIS cells, orange arrows – Sertoli cells. e and f Gankyrin (red), POU5F1 (green; seminoma cells), and MAGE-A4 (blue) expression in seminoma cells (e) and a mixed TGCC (e), inset on D – no primary antibody control. Scalebars - 50 μm.

Knock-down of Gankyrin expression in NTera2 cells results in a reduction in cell number without effects on POU5F1 expression

To investigate the role of Gankyrin in malignant germ cells, we used the embryonal carcinoma cell line (NTera2) to perform Gankyrin knock-down in vitro using an siRNA approach. Gankyrin mRNA expression was significantly reduced (62%; p < 0.001) after 24 h, with a similar reduction (50%; p < 0.01) at the protein level (Fig. 4a and b). The reduction in Gankyrin expression did not affect POU5F1 expression at either the mRNA or protein level (Fig. 4c-e).
Fig. 4

Effects of Gankyrin knock-down on Gankyrin and POU5F1 expression. Relative Gankyrin mRNA(a) and protein (b) expression in NTera2 cells after Gankyrin knock-down. Relative POU5F1 mRNA (c) and protein (d) expression in NTera2 cells after Gankyrin knock-down. e Representative Western blot for Gankyrin and POU5F1 expression in (V) vehicle and Gankyrin siRNA (T) transfected NTera2 cells. Tubulin was used as a loading control. Data analysed by paired t-test ± SEM, ***p < 0.001, **p < 0.01. Each data point represents the mean of an individualexperiment, each with 3 replicates. Paired samples from an individual experiment are represented by the same colour.

Knock-down of Gankyrin expression resulted in a significant reduction in the number of NTera2 cells (32%; p < 0.01, Fig. 5a). To investigate this further, we determined the expression of genes involved in cell proliferation. Gankyrin knock-down did not affect the expression of either PCNA or Ki67 (Fig. 5b and c); however, cell cycle analysis demonstrated a small but significant increase (4%; p < 0.05) in the proportion of NTera2 cell in G0/G1 phase, with no significant effects on other phases of the cell cycle (Fig. 5d-g).
Fig. 5

Effect of Gankyrin knock-down on cell number, cell proliferation and cell cycle of NTera2 cells. a Gankyrin knock-down effect on NTera2 cell number. Relative PCNA (b) and ki67 (c) expression after 24 h of Gankyrin siRNA transfection. Distribution of NTera2 cells in GO/G1 phase (d), G2/M phase (e) or S phase (f). Data analysed by paired t-test, means ± SEM, ** p < 0.001, *p < 0.05. Each data point represents the mean of an individual experiment, each with an 3 replicates. Paired samples from an individual experiment are represented by the same colour. (g) Representative image of the flow cytometry plot obtained during cell cycle experiments.

To determine whether the effects on cell number involved activation of apoptosis and/or cell cycle arrest, we investigated the TP53 pathway (Fig. 6, A). Knock-down of Gankyrin expression resulted in a significant increase in TP53 expression (Fig. 6b) and several downstream genes including P21, BAX, FAS, and PAI-I (Fig. 6c-g). Functional image-based analysis using a cell-permeable fluorescent caspase biosensor revealed knockdown of Gankyrin resulted in activation of Cleaved Caspase 3 (CC3) mediated apoptosis, whilst no apoptotic cells were identified in controls (Fig. 6h).
Fig. 6

Gankyrin knock-down effect on TP53 and apoptosis. a TP53 pathway showing genes of interest in this study. Relative (b) TP53 (n = 4), (c) P21 (n = 4), (d) BAX (n = 4), (e) FAS (n = 4), (f) BAI-1 (n = 6), (g) PAI-1 (n = 7) mRNA expression in NTera2 cells after Gankyrin knock-down. Data (b-g) analysed by paired t-test, means ±SEM, *p < 0.05, **; p < 0.001. Each data point represents the mean of an individual experiment, each with 3 replicates. Paired samples from an individual experiment are represented by the same colour. H) Effects of Gankyrin knock-down on apoptosis in NT2 cells using Nucview apoptosis (CC3) probe. Representative images of four separate experiments, each with 3 replicates.

Gankyrin knock-down enhances cisplatin mediated cell death in NTera2 cell

TP53 has been shown to be important in mediating the cytotoxic effect of cisplatin in TGCC [33, 43, 44], therefore we investigated the role of Gankyrin in cisplatin sensitivity in NTera2 cells. We confirmed the siRNA mediated knock-down of Gankyrin expression in cisplatin exposed NTera2 cells (Fig. 7a), and found that this resulted in a significant reduction in the percentage of recovered live cells compared to non-transfected untreated controls (80%, p < 0.05) and non-transfected cisplatin treated controls (50%, p < 0.05) (Fig. 7b). There was no effect of Gankyrin knock-down on TP53 mRNA or protein expression (Fig. 7c-e) however there was a significant increase in FAS mRNA expression in cisplatin transfected cells (Fig. 7f).
Fig. 7

Effect of Gankyrin knock-down on cisplatin sensitivity in NTera2 cells. a Gankyrin mRNA expression after Gankyrin knock-down in cisplatin (20 nM) exposed NTera2 cells. b Gankyrin knock-down and cisplatin treatment effect on the percentage of surviving cells Gankyrin knock-down and cisplatin treatment effects on (c) TP53 mRNA and (d) protein expression. e Representative image for TP53 western blot in Vehicle (V) and Gankyrin siRNA transfected (T) samples with and without cisplatin treatment and a no treatment control (NT). f Relative FAS mRNA expression after Gankyrin knock-down and cisplatin treatment. CTL: control, CISP: cisplatin, VEH + CISP: vehicle and cisplatin, siRNA+CISP: Gankyrin siRNA+cisplatin. Data analysed by paired t-test, means ±SEM, **p < 0.001, *p < 0.05. Each data point represents the mean of an individual experiment, each with 3 replicates. Paired samples from an individual experiment are represented by the same colour.

Discussion

The present study represents the first description of Gankyrin expression in the normal human testis, testis with maturation delay and in GCNIS from patients with pre-invasive and invasive TGCC. In the human fetal testis, we have shown that whilst nuclear expression of Gankyrin was not detected in gonocytes (POU5F1+), nuclear Gankyrin was observed in the nuclei of a sub-set of (pre) spermatogonia (MAGE-A4+). This suggest Gankyrin might be involved in normal germ cell differentiation. GCNIS is believed to result from failure of differentiation from gonocyte (POU5F1+) to (pre) spermatogonia (POU5F1) [4, 5]. Our observation that nuclear Gankyrin is not expressed in gonocytes (POU5F1+/Gankyrin) but expressed in gonocytes from samples with maturation delay and pre-GCNIS (POU5F1+/Gankyrin+) indicates that Gankyrin expression is associated with the early stage of TGCC development. Furthermore, within the GCNIS cell populations, Gankyrin expression is present in a higher proportion of POU5F1+/MAGE-A4 compared with POU5F1+/MAGE-A4+cells, which may reflect an increased oncogenic potential in the in the more proliferative POU5F1+/MAGE-A4 population [45].

Previous studies have demonstrated that Gankyrin prevents POU5F1 degradation in HCC [23] and loss of Gankyrin can reduce the oncogenic potential of tumour cells through interaction with MAGE-A4 [26]. This, combined with our previous finding of reduced oncogenic potential in the POU5F1+/MAGE-A4+ population of GCNIS cells compared with POU5F1+/MAGE-A4 population [14] led us to hypothesize that Gankyrin expression might play a similar role in the pathogenesis of TGCC by preventing POU5F1 degradation and contributing to malignant progression.

Therefore, we investigated the effects of Gankyrin knock-down in NTera2 cells, an established embryonal carcinoma cell line which is widely used in studies relating to TGCC [6, 46, 47, 48]. Transfection with siRNA targeting Gankyrin resulted in a significant reduction (62%; p < 0.001) in Gankyrin expression. Gankyrin knock-down did not affect POU5F1 mRNA or protein expression in NTera2 cells demonstrating that Gankyrin does not prevent POU5F1 degradation in this cell line. Interestingly, we did find that Gankyrin knock-down led to a significant reduction in cell number suggesting a possible role for this protein in the survival of malignant germ cells. Several studies have demonstrated effect of Gankyrin on oncogenic potential in hepatocellular carcinoma cells due to increased cell proliferation and malignant transformation of normal hepatocytes [20, 23, 24, 49, 50].

Given that knock-down of Gankyrin expression did not affect the mRNA expression levels of proliferation markers and induced only minor changes in the proportion of cells in the different phases of cell cycle, we speculated that the reduction in cell number may be as a result of an increase in apoptosis. A number of pro-apoptotic genes are located downstream of TP53 and we found that TP53 expression is upregulated following knock-down of Gankyrin in NTera2 cells, which is in keeping with the results of a previous study [36]. Furthermore, we have demonstrated that Gankyrin knock-down results in an increased expression of apoptosis genes BAX and FAS, both of which are downstream of TP53. Down-regulation of Gankyrin also induces apoptosis in hepatocellular carcinoma cells with wild type TP53 [35] whilst increased expression of Gankyrin inhibits apoptosis by causing degradation of TP53 protein and reduced transcription of its downstream apoptotic genes [35]. Furthermore, apoptotis was induced following Gankyrin down-regulation, as indicated by Cleaved Caspase 3 activity. Taken together these results suggest that following Gankyrin knock-down in NTera2 cells the reduction in cell number is likely to be mediated by an increase in apoptosis mediated through the TP53 signalling pathway leading to increased expression of the apoptotic genes BAX and FAS.

Cisplatin, is the chemotherapeutic drug of choice for treatment of TGCC, acting through the TP53 pathway to induce DNA damage [33]. The expression of wildtype TP53 in TGCC has been proposed to be a key determinant for the effectiveness of cisplatin treatment [30]. This might be related to the expression of a selected number of embryonic microRNAs [51]. Previous studies have reported that TP53 mutations did not occur in TGCC [52], however recent studies have shown that 10 out of 148 patients with seminoma (7%) have a TP53 mutation [53]. Although TP53 is abundantly present in its wildtype form in TGCC, it has also been suggested that TP53 is inactive in TGCC, given that its downstream genes have been indicated as non-detectable [30]. Recent studies have demonstrated that knockdown of TP53 in NTera2 cells resulted in reduced cisplatin mediated apoptosis [33, 34]. Therefore, given that we identified an effect of Gankyrin knock-down on the TP53 and BAX/FAS apoptosis pathway, we speculated that manipulation of Gankyrin might modulate the effect of cisplatin in TGCC. To test this, we combined Gankyrin knock-down with cisplatin treatment in NTera2 cells. We showed that Gankyrin knock-down enhances the reduction in cell number caused by cisplatin treatment by 13% (p < 0.05), compared to cisplatin treatment alone. Taken together, these results suggest that Gankyrin plays a role in cisplatin sensitivity and resistance.

Conclusion

In conclusion, we have demonstrated that Gankyrin is expressed in the sub-populations of germ cells in the normal fetal and adult testis, as well as in pre-invasive and invasive TGCC tissue from patients. We have also demonstrated that repression of Gankyrin in NTera2 cells results in a reduction in total cell number and enhances the cytotoxic effect of cisplatin in this TGCC cell line. Together our results suggest that Gankyrin may be a potential target for treatment of TGCC either as an adjunct to cisplatin or in cisplatin resistant tumours.

Notes

Acknowledgements

We thank Pierre Rome and John Dawson for their technical assistance.

Authors’ contributions

Conceived and designed the experiments: M.E.C-M, A. J, R.T.M. Performed the experiments: M.E.C.M, M.P.R. Analyzed the data: M.E.C.M, J. M, A.J, R.T.M. Contributed reagents/materials/analysis tools and expertise: L. L, R. D, C.J.S, N. C, J.A.M. Wrote the paper: M.E.C.M., A. J, R.T.M. All authors approved the submitted version.

Funding

M.E.C.M was funded by a PhD studentship award (CONACYT, Mexico) and a University of Edinburgh Charles Darwin Scholarship. This project was funded by a Wellcome Trust Intermediate Clinical Fellowship (Grant no. 098522) awarded to R.T.M. The funders had no involvement in the design of the study or in collection, analysis, and interpretation of data and in writing the manuscript.

Ethics approval and consent to participate

For human fetal tissues, pregnant women undergoing elective termination gave informed consent and tissue was collected with ethical approval. This project is registered and approved under the project numbers: REC reference: LREC08/1101/1 and 08/H0906/21 + 5. Ethical approval was obtained for collection of postnatal human testis samples from Western General Hospital in Edinburgh (REC Reference: 10/S1402/33), Erasmus MC-University Medical Center, Rotterdam (MEC 02.981 and CCR2041) and University Hospital of Copenhagen, Copenhagen, Denmark (H-1-2012-007). Written informed consent was obtained for the use of all tissues included in the study.

Consent for publication

The study involves the use of tissues from anonymised and non-identifiable patients.

Competing interests

The authors declare that they have no competing interests.

Supplementary material

12885_2019_6340_MOESM1_ESM.tif (27 kb)
Additional file 1 Figure S1. Nuclear Gankyrin expression in POU5F1+/MAGE-A4 GCNIS cells and in POU5F1+/MAGE-A4+ GCNIS cells in samples from pre-invasive GCNIS and invasive TGCC patients (n = 12). Data analysed by paired t-test, means ± SEM.

References

  1. 1.
    Schottenfeld D, Warshauer ME, Sherlock S, Zauber AG, Leder M, Payne R. The epidemiology of testicular cancer in young adults. Am J Epidemiol 1980;112:232–246. http://www.ncbi.nlm.nih.gov/pubmed/6106385. Accessed 13 Dec 2013.CrossRefGoogle Scholar
  2. 2.
    Giwercman A, Carlsen E, Keiding N, Skakkebaek NE. Evidence for increasing incidence of abnormalities of the human testis: a review. Environ Health Perspect 1993;101 Suppl:65–71. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1519947&tool=pmcentrez&rendertype=abstract. Accessed 14 Jan 2014.
  3. 3.
    Bray F, Richiardi L, Ekbom A, Pukkala E, Cuninkova M, Møller H. Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer. 2006;118:3099–111.  https://doi.org/10.1002/ijc.21747.CrossRefPubMedGoogle Scholar
  4. 4.
    Skakkebaek NE, Berthelsen JG, Giwercman A, Müller J. Carcinoma-in-situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int J Androl 1987;10:19–28. http://www.ncbi.nlm.nih.gov/pubmed/3034791. Accessed 13 Dec 2013.CrossRefGoogle Scholar
  5. 5.
    Hoei-Hansen CE, Almstrup K, Nielsen JE, Brask Sonne S, Graem N, Skakkebaek NE, et al. Stem cell pluripotency factor NANOG is expressed in human fetal gonocytes, testicular carcinoma in situ and germ cell tumours. Histopathology. 2005;47:48–56.  https://doi.org/10.1111/j.1365-2559.2005.02182.x.CrossRefPubMedGoogle Scholar
  6. 6.
    Almstrup K, Hoei-Hansen CE, Wirkner U, Blake J, Schwager C, Ansorge W, et al. Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling. Cancer Res. 2004;64:4736–43.  https://doi.org/10.1158/0008-5472.CAN-04-0679.CrossRefPubMedGoogle Scholar
  7. 7.
    Almstrup K, Nielsen JE, Mlynarska O, Jansen MT, Jørgensen A, Skakkebæk NE, et al. Carcinoma in situ testis displays permissive chromatin modifications similar to immature foetal germ cells. Br J Cancer. 2010;103:1269–76.  https://doi.org/10.1038/sj.bjc.6605880.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Sonne SB, Almstrup K, Dalgaard M, Juncker AS, Edsgard D, Ruban L, et al. Analysis of gene expression profiles of microdissected cell populations indicates that testicular carcinoma in situ is an arrested gonocyte. Cancer Res. 2009;69:5241–50.  https://doi.org/10.1158/0008-5472.CAN-08-4554.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Rajpert-De Meyts E, Jørgensen N, Brøndum-Nielsen K, Müller J, Skakkebaek NE. Developmental arrest of germ cells in the pathogenesis of germ cell neoplasia. APMIS 1998;106:198–204; discussion 204-6. http://www.ncbi.nlm.nih.gov/pubmed/9524579. Accessed 14 Jul 2016.CrossRefGoogle Scholar
  10. 10.
    Chaganti RS, Houldsworth J. Genetics and biology of adult human male germ cell tumors. Cancer Res 2000;60:1475–1482. http://www.ncbi.nlm.nih.gov/pubmed/10749107. Accessed 14 Jul 2016.
  11. 11.
    George J. Bosl, M.D., and Robert J. Motzer MD, Bosl GJ, Motzer RJ. Testicular germ-cell Cancer. N Engl J Med 1997;337:242–253. doi: https://doi.org/10.1056/NEJM199707243370406.CrossRefGoogle Scholar
  12. 12.
    Rajpert-De Meyts E, McGlynn KA, Okamoto K, Jewett MAS, Bokemeyer C. Testicular germ cell tumours. Lancet. 2016;387:1762–74.  https://doi.org/10.1016/S0140-6736(15)00991-5.CrossRefPubMedGoogle Scholar
  13. 13.
    Cheng L, Albers P, Berney DM, Feldman DR, Daugaard G, Gilligan T, et al. Testicular cancer. Nat Rev Dis Prim. 2018;4:29.  https://doi.org/10.1038/s41572-018-0029-0.CrossRefPubMedGoogle Scholar
  14. 14.
    Mitchell RT, E Camacho-Moll M, Macdonald J, Anderson RA, Kelnar CJH, Sharpe RM, et al. Intratubular germ cell neoplasia of the human testis: heterogeneous protein expression and relation to invasive potential. Mod Pathol 2014;27:1255–1266. doi: https://doi.org/10.1038/modpathol.2013.246.CrossRefGoogle Scholar
  15. 15.
    Tang S, Yang G, Meng Y, Du R, Li X, Fan R, et al. Overexpression of a novel gene gankyrin correlates with the malignant phenotype of colorectal cancer. Cancer Biol Ther 2010;9:88–95. http://www.ncbi.nlm.nih.gov/pubmed/19901563. Accessed 24 May 2016.CrossRefGoogle Scholar
  16. 16.
    Bai Z, Tai Y, Li W, Zhen C, Gu W, Jian Z, et al. Gankyrin activates IL-8 to promote hepatic metastasis of colorectal cancer. Cancer Res. 2013;73:4548–58.  https://doi.org/10.1158/0008-5472.CAN-12-4586.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhen C, Chen L, Zhao Q, Liang B, Gu Y-X, Bai Z-F, et al. Gankyrin promotes breast cancer cell metastasis by regulating Rac1 activity. Oncogene. 2013;32356:3452–60.  https://doi.org/10.1038/onc.2012.356.CrossRefGoogle Scholar
  18. 18.
    Kim YH, Kim J-H, Choi YW, Lim SK, Yim H, Kang SY, et al. Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression. Exp Mol Pathol. 2013;94:360–5.  https://doi.org/10.1016/j.yexmp.2012.12.002.CrossRefPubMedGoogle Scholar
  19. 19.
    Gao L, Xie H, Dong L, Zou J, Fu J, Gao X, et al. Gankyrin is essential for hypoxia enhanced metastatic potential in breast cancer cells. Mol Med Rep 2014;9:1032–1036. http://www.spandidos-publications.com/mmr/9/3/1032/abstract. Accessed 14 May 2014.CrossRefGoogle Scholar
  20. 20.
    Jing H, Zhang G, Meng L, Meng Q, Mo H, Tai Y. Gradually elevated expression of Gankyrin during human hepatocarcinogenesis and its clinicopathological significance. Sci Rep. 2014;4:5503.  https://doi.org/10.1038/srep05503.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Fu X-Y, Wang H-Y, Tan L, Liu S-Q, Cao H-F, Wu M-C. Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance. World J Gastroenterol. 2002;8:638–43.  https://doi.org/10.3748/WJG.V8.I4.638.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Dong L, Yang G, Pan Y, Chen Y, Tan Y, Dai R, et al. The oncoprotein p28GANK establishes a positive feedback loop in β-catenin signaling. Cell Res. 2011;21:1248–61.  https://doi.org/10.1038/cr.2011.103.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Qian Y-W, Chen Y, Yang W, Fu J, Cao J, Ren Y-B, et al. p28(GANK) prevents degradation of Oct4 and promotes expansion of tumor-initiating cells in hepatocarcinogenesis. Gastroenterology. 2012;142:1547–58.e14.  https://doi.org/10.1053/j.gastro.2012.02.042.CrossRefPubMedGoogle Scholar
  24. 24.
    Higashitsuji H, Itoh K, Nagao T, Dawson S, Nonoguchi K, Kido T, et al. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med. 2000;6:96–9.  https://doi.org/10.1038/71600.CrossRefPubMedGoogle Scholar
  25. 25.
    Song X, Wang J, Zheng T, Song R, Liang Y, Bhatta N, et al. LBH589 inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway. Mol Cancer. 2013;12:114.  https://doi.org/10.1186/1476-4598-12-114.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Nagao T, Higashitsuji H, Nonoguchi K, Sakurai T, Dawson S, Mayer RJ, et al. MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem. 2003;278:10668–74.  https://doi.org/10.1074/jbc.M206104200.CrossRefPubMedGoogle Scholar
  27. 27.
    Xu H, Wang W, Li C, Yu H, Yang A, Wang B, et al. WWP2 promotes degradation of transcription factor OCT4 in human embryonic stem cells. Cell Res. 2009;19:561–73.  https://doi.org/10.1038/cr.2009.31.CrossRefPubMedGoogle Scholar
  28. 28.
    Dieckmann KP, Skakkebaek NE. Carcinoma in situ of the testis: review of biological and clinical features. Int J Cancer 1999;83:815–822. http://www.ncbi.nlm.nih.gov/pubmed/10597201. Accessed 23 Mar 2018.CrossRefGoogle Scholar
  29. 29.
    Oosterhuis JW, Looijenga LHJ. Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer. 2005;5:210–22.  https://doi.org/10.1038/nrc1568.CrossRefPubMedGoogle Scholar
  30. 30.
    Guillou L, Estreicher A, Chaubert P, Hurlimann J, Kurt AM, Metthez G, et al. Germ cell tumors of the testis overexpress wild-type p53. Am J Pathol 1996;149:1221–1228. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1865176&tool=pmcentrez&rendertype=abstract. Accessed 13 May 2014.
  31. 31.
    Koster R, van Vugt MATM, Timmer-Bosscha H, Gietema JA, de Jong S. Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer. Expert Rev Mol Med. 2013;15:e12.  https://doi.org/10.1017/erm.2013.13.CrossRefPubMedGoogle Scholar
  32. 32.
    Bragado P, Armesilla A, Silva A, Porras A. Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis. 2007;12:1733–42.  https://doi.org/10.1007/s10495-007-0082-8.CrossRefPubMedGoogle Scholar
  33. 33.
    Gutekunst M, Oren M, Weilbacher A, Dengler MA, Markwardt C, Thomale J, et al. p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin. PLoS One. 2011;6:e19198.  https://doi.org/10.1371/journal.pone.0019198.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Bauer S, Mühlenberg T, Leahy M, Hoiczyk M, Gauler T, Schuler M, et al. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours. Eur Urol. 2010;57:679–87.  https://doi.org/10.1016/j.eururo.2009.06.014.CrossRefPubMedGoogle Scholar
  35. 35.
    Higashitsuji H, Higashitsuji H, Itoh K, Sakurai T, Nagao T, Sumitomo H, et al. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell. 2005;8:75–87.CrossRefGoogle Scholar
  36. 36.
    Chen B-F, Suen Y-K, Gu S, Li L, Chan W-Y. A miR-199a/miR-214 self-regulatory network via PSMD10, TP53 and DNMT1 in testicular germ cell tumor. Sci Rep. 2014;4:6413.  https://doi.org/10.1038/srep06413.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Ando S, Matsuoka T, Kawai K, Sugita S, Joraku A, Kojima T, et al. Expression of the oncoprotein gankyrin and phosphorylated retinoblastoma protein in human testis and testicular germ cell tumor. Int J Urol. 2014;21:992–8.  https://doi.org/10.1111/iju.12484.CrossRefPubMedGoogle Scholar
  38. 38.
    Friel A, Houghton JA, Glennon M, Lavery R, Smith T, Nolan A, et al. A preliminary report on the implication of RT-PCR detection of DAZ, RBMY1, USP9Y and Protamine-2 mRNA in testicular biopsy samples from azoospermic men. Int J Androl. 2002;25:59–64.  https://doi.org/10.1046/j.1365-2605.2002.00326.x.CrossRefPubMedGoogle Scholar
  39. 39.
    Spoor JA, Oosterhuis JW, Hersmus R, Biermann K, Wolffenbuttel KP, Cools M, et al. Histological assessment of gonads in DSD: relevance for clinical management. Sex Dev. 2018;12:106–22.  https://doi.org/10.1159/000481757.CrossRefPubMedGoogle Scholar
  40. 40.
    Aubry F, Satie AP, Rioux-Leclercq N, Rajpert-De Meyts E, Spagnoli GC, Chomez P, et al. MAGE-A4, a germ cell specific marker, is expressed differentially in testicular tumors. Cancer. 2001;92:2778–85 http://www.ncbi.nlm.nih.gov/pubmed/11753951. .CrossRefGoogle Scholar
  41. 41.
    Landry C, Brasseur F, Spagnoli GC, Marbaix E, Boon T, Coulie P, et al. Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. Int J Cancer. 2000;86:835–41 http://www.ncbi.nlm.nih.gov/pubmed/10842198. .CrossRefGoogle Scholar
  42. 42.
    Svingen T, Jørgensen A, Rajpert-De ME. Validation of endogenous normalizing genes for expression analyses in adult human testis and germ cell neoplasms. MHR Basic Sci Reprod Med. 2014;20:709–18.  https://doi.org/10.1093/molehr/gau030.CrossRefGoogle Scholar
  43. 43.
    Chee JLY, Saidin S, Lane DP, Leong SM, Noll JE, Neilsen PM, et al. Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9. Cell Cycle. 2013;12:278–88.  https://doi.org/10.4161/cc.23054.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    di Pietro A, Koster R, Boersma-van Eck W, Dam WA, Mulder NH, Gietema JA, et al. Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent. Cell Cycle. 2012;11:4552–62.  https://doi.org/10.4161/cc.22803.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Mitchell RT, E Camacho-Moll M, Macdonald J, Anderson RA, Kelnar CJH, Sharpe RM, et al. Intratubular germ cell neoplasia of the human testis: heterogeneous protein expression and relation to invasive potential Mod Pathol 2014. doi: https://doi.org/10.1038/modpathol.2013.246.CrossRefGoogle Scholar
  46. 46.
    Mueller S, Schittenhelm M, Honecker F, Malenke E, Lauber K, Wesselborg S, et al. Cell-cycle progression and response of germ cell tumors to cisplatin in vitro. Int J Oncol 2006;29:471–479. http://www.ncbi.nlm.nih.gov/pubmed/16820891. Accessed 22 Oct 2015.
  47. 47.
    Cheng C-J, Wu Y-C, Shu J-A, Ling T-Y, Kuo H-C, Wu J-Y, et al. Aberrant expression and distribution of the OCT-4 transcription factor in seminomas. J Biomed Sci. 2007;14:797–807.  https://doi.org/10.1007/s11373-007-9198-7.CrossRefPubMedGoogle Scholar
  48. 48.
    Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 2013;23:1422–33.  https://doi.org/10.1101/gr.154492.113.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Higashitsuji H, Liu Y, Mayer RJ, Fujita J. The oncoprotein gankyrin negatively regulates both p53 and RB by enhancing proteasomal degradation. Cell Cycle. 2005;4:1335–7.  https://doi.org/10.4161/cc.4.10.2107.CrossRefPubMedGoogle Scholar
  50. 50.
    Iwai A, Marusawa H, Kiuchi T, Higashitsuji H, Tanaka K, Fujita J, et al. Role of a novel oncogenic protein, gankyrin, in hepatocyte proliferation. J Gastroenterol. 2003;38:751–8.  https://doi.org/10.1007/s00535-003-1141-8.CrossRefPubMedGoogle Scholar
  51. 51.
    Voorhoeve PM, le Sage C, Schrier M, Gillis AJM, Stoop H, Nagel R, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Adv Exp Med Biol 2007;604:17–46. http://www.ncbi.nlm.nih.gov/pubmed/17695719. Accessed 8 Feb 2019.
  52. 52.
    Peng HQ, Hogg D, Malkin D, Bailey D, Gallie BL, Bulbul M, et al. Mutations of the p53 gene do not occur in testis cancer. Cancer Res 1993;53:3574–3578. http://www.ncbi.nlm.nih.gov/pubmed/8339263. Accessed 8 Feb 2016.
  53. 53.
    Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, et al. Cosmic 2005. Br J Cancer. 2006;94:318–22.  https://doi.org/10.1038/sj.bjc.6602928.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Maria E. Camacho-Moll
    • 1
    • 2
  • Joni Macdonald
    • 3
  • L. H. J. Looijenga
    • 4
    • 5
  • Michael P. Rimmer
    • 3
  • Roland Donat
    • 6
  • John A. Marwick
    • 7
  • C. J. Shukla
    • 6
  • Neil Carragher
    • 8
  • Anne Jørgensen
    • 9
  • Rod T. Mitchell
    • 3
    Email author
  1. 1.Departamento de Biología MolecularCentro de Investigación Biomédica del Noreste, Delegación Nuevo León, Instituto Mexicano del Seguro SocialMonterreyMexico
  2. 2.Centro de Diagnóstico Molecular y Medicina Personalizada, División Ciencias de la SaludUniversidad de Monterrey, Av. Ignacio Morones Prieto 4500 PteSan Pedro Garza GarcíaMexico
  3. 3.MRC Centre for Reproductive HealthThe University of Edinburgh, Queen’s Medical Research InstituteScotlandUK
  4. 4.Department of PathologyErasmus University, Medical Center, Cancer Center, Josephine Nefkens InstituteRotterdamNetherlands
  5. 5.Princess Maxima Center for Pediatric OncologyUtrechtThe Netherlands
  6. 6.Department of Urology, Western General Hospital, Crewe RoadScotlandUK
  7. 7.The MRC Centre for Inflammation Research, Queen’s Medical Research InstituteEdinburghUK
  8. 8.Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular MedicineEdinburghUK
  9. 9.Department of Growth and ReproductionUniversity Hospital of CopenhagenCopenhagenUK

Personalised recommendations